Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria
Crossref DOI link: https://doi.org/10.1007/s00520-017-3610-2
Published Online: 2017-02-15
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dranitsaris, George http://orcid.org/0000-0002-1637-3122
Shane, Lesley G
Galanaud, Jean-Philippe
Stemer, Gunar
Debourdeau, Philippe
Woodruff, Seth
Funding for this research was provided by:
Pfizer (0000-0002-1637-3122)
License valid from 2017-02-15